CytomX Therapeutics ROA 2014-2022 | CTMX

Current and historical return on assets (ROA) values for CytomX Therapeutics (CTMX) over the last 10 years. Return on assets can be defined as an indicator of how profitable a company is relative to its total assets. Calculated by dividing a company's operating earnings by its total assets.
CytomX Therapeutics ROA - Return on Assets Historical Data
Date TTM Net Income Total Assets Return on Assets
2022-09-30 $-0.10B $0.23B -34.58%
2022-06-30 $-0.10B $0.26B -30.62%
2022-03-31 $-0.09B $0.30B -26.12%
2021-12-31 $-0.08B $0.34B -21.73%
2021-09-30 $-0.07B $0.37B -18.65%
2021-06-30 $-0.07B $0.40B -16.56%
2021-03-31 $-0.06B $0.43B -15.80%
2020-12-31 $-0.03B $0.36B -8.65%
2020-09-30 $-0.05B $0.38B -13.89%
2020-06-30 $-0.06B $0.40B -16.23%
2020-03-31 $-0.08B $0.44B -19.54%
2019-12-31 $-0.10B $0.34B -26.09%
2019-09-30 $-0.10B $0.37B -23.57%
2019-06-30 $-0.10B $0.41B -21.90%
2019-03-31 $-0.08B $0.45B -18.62%
2018-12-31 $-0.08B $0.46B -19.61%
2018-09-30 $-0.05B $0.48B -12.24%
2018-06-30 $-0.04B $0.38B -9.62%
2018-03-31 $-0.05B $0.38B -12.95%
2017-12-31 $-0.04B $0.40B -12.78%
2017-09-30 $-0.06B $0.39B -20.43%
2017-06-30 $-0.06B $0.35B -26.90%
2017-03-31 $-0.05B $0.18B -26.25%
2016-12-31 $-0.06B $0.20B -29.84%
2016-09-30 $-0.06B $0.19B -28.90%
2016-06-30 $-0.06B $0.21B -31.62%
2016-03-31 $-0.05B $0.19B -39.69%
2015-12-31 $-0.04B $0.20B -53.42%
2015-06-30 $-0.02B $0.00B inf%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.115B $0.070B
CytomX Therapeutics, Inc. is an oncology focused biopharmaceutical company. The Company is engaged in developing Probody(TM) therapeutics for the treatment of cancer. Its pipeline focuses areas consist of Precision cancer immunotherapy and Probody drug conjugates. CytomX Therapeutics, Inc. is headquartered in South San Francisco, California.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $141.122B 8.73
GSK (GSK) United Kingdom $75.233B 9.43
Bio-Rad Laboratories (BIO.B) United States $13.735B 32.61
QIAGEN (QGEN) Netherlands $10.461B 19.38
Ginkgo Bioworks Holdings (DNA) United States $2.529B 0.00
Arcus Biosciences (RCUS) United States $1.165B 0.00
Biohaven (BHVN) United States $0.882B 0.00
Emergent Biosolutions (EBS) United States $0.391B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.153B 0.00
Enzo Biochem (ENZ) United States $0.102B 0.00
SQZ Biotechnologies (SQZ) United States $0.018B 0.00
Gelesis Holdings (GLS) United States $0.011B 0.00